144 related articles for article (PubMed ID: 24377588)
1. Risk of treatment-related mortality with sorafenib in patients with cancer.
Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; Xu F; Wei LX; He J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6681-6. PubMed ID: 24377588
[TBL] [Abstract][Full Text] [Related]
2. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Gyawali B; Shimokata T; Ando M; Honda K; Ando Y
Ann Oncol; 2017 Feb; 28(2):246-253. PubMed ID: 27771613
[TBL] [Abstract][Full Text] [Related]
3. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
Yang X; Pan X; Cheng X; Cheng Y; Kuang Y
Int J Clin Pharm; 2015 Dec; 37(6):1047-56. PubMed ID: 26173936
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
5. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.
Cao M; Li F; Wang Y; Zhang J
Invest New Drugs; 2017 Dec; 35(6):834-838. PubMed ID: 28936569
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
Sivendran S; Liu Z; Portas LJ; Yu M; Hahn N; Sonpavde G; Oh WK; Galsky MD
Cancer Treat Rev; 2012 Nov; 38(7):919-25. PubMed ID: 22651902
[TBL] [Abstract][Full Text] [Related]
9. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Wang WL; Tang ZH; Xie TT; Xiao BK; Zhang XY; Guo DH; Wang DX; Pei F; Si HY; Zhu M
Asian Pac J Cancer Prev; 2014; 15(14):5691-6. PubMed ID: 25081687
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.
Qi WX; Tang LN; Shen Z; Yao Y
Eur J Clin Pharmacol; 2014 Apr; 70(4):461-7. PubMed ID: 24390630
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
13. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
[TBL] [Abstract][Full Text] [Related]
14. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Chu D; Lacouture ME; Fillos T; Wu S
Acta Oncol; 2008; 47(2):176-86. PubMed ID: 18210295
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
[TBL] [Abstract][Full Text] [Related]
16. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Future Oncol; 2014 Oct; 10(12):1981-92. PubMed ID: 25386814
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Li Y; Li S; Zhu Y; Liang X; Meng H; Chen J; Zhang D; Guo H; Shi B
J Clin Hypertens (Greenwich); 2014 Mar; 16(3):177-85. PubMed ID: 24621095
[TBL] [Abstract][Full Text] [Related]
19. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.
Sher AF; Golshani GM; Wu S
Cancer Invest; 2020 Feb; 38(2):130-138. PubMed ID: 31985314
[No Abstract] [Full Text] [Related]
20. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
